OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
TEL AVIV, Israel, Aug. 28, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will provide a corporate overview at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
Presentation Details:
Date: Monday, September 11, 2017
Time: 2:35-3:00 PM Eastern Time
Location: Holmes II; Lotte New York Palace Hotel in New York City
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC [email protected] (646) 597-6979 MEDIA CONTACT: Matt Middleman, M.D. LifeSci Public Relations [email protected] (646) 627-8384
